Cargando…

A Stromal Immune Module Correlated with the Response to Neoadjuvant Chemotherapy, Prognosis and Lymphocyte Infiltration in HER2-Positive Breast Carcinoma Is Inversely Correlated with Hormonal Pathways

INTRODUCTION: HER2-positive breast cancer (BC) is a heterogeneous group of aggressive breast cancers, the prognosis of which has greatly improved since the introduction of treatments targeting HER2. However, these tumors may display intrinsic or acquired resistance to treatment, and classifiers of H...

Descripción completa

Detalles Bibliográficos
Autores principales: Hamy, Anne-Sophie, Bonsang-Kitzis, Hélène, Lae, Marick, Moarii, Matahi, Sadacca, Benjamin, Pinheiro, Alice, Galliot, Marion, Abecassis, Judith, Laurent, Cecile, Reyal, Fabien
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5178998/
https://www.ncbi.nlm.nih.gov/pubmed/28005906
http://dx.doi.org/10.1371/journal.pone.0167397
_version_ 1782485292986400768
author Hamy, Anne-Sophie
Bonsang-Kitzis, Hélène
Lae, Marick
Moarii, Matahi
Sadacca, Benjamin
Pinheiro, Alice
Galliot, Marion
Abecassis, Judith
Laurent, Cecile
Reyal, Fabien
author_facet Hamy, Anne-Sophie
Bonsang-Kitzis, Hélène
Lae, Marick
Moarii, Matahi
Sadacca, Benjamin
Pinheiro, Alice
Galliot, Marion
Abecassis, Judith
Laurent, Cecile
Reyal, Fabien
author_sort Hamy, Anne-Sophie
collection PubMed
description INTRODUCTION: HER2-positive breast cancer (BC) is a heterogeneous group of aggressive breast cancers, the prognosis of which has greatly improved since the introduction of treatments targeting HER2. However, these tumors may display intrinsic or acquired resistance to treatment, and classifiers of HER2-positive tumors are required to improve the prediction of prognosis and to develop novel therapeutic interventions. METHODS: We analyzed 2893 primary human breast cancer samples from 21 publicly available datasets and developed a six-metagene signature on a training set of 448 HER2-positive BC. We then used external public datasets to assess the ability of these metagenes to predict the response to chemotherapy (Ignatiadis dataset), and prognosis (METABRIC dataset). RESULTS: We identified a six-metagene signature (138 genes) containing metagenes enriched in different gene ontologies. The gene clusters were named as follows: Immunity, Tumor suppressors/proliferation, Interferon, Signal transduction, Hormone/survival and Matrix clusters. In all datasets, the Immunity metagene was less strongly expressed in ER-positive than in ER-negative tumors, and was inversely correlated with the Hormonal/survival metagene. Within the signature, multivariate analyses showed that strong expression of the “Immunity” metagene was associated with higher pCR rates after NAC (OR = 3.71[1.28–11.91], p = 0.019) than weak expression, and with a better prognosis in HER2-positive/ER-negative breast cancers (HR = 0.58 [0.36–0.94], p = 0.026). Immunity metagene expression was associated with the presence of tumor-infiltrating lymphocytes (TILs). CONCLUSION: The identification of a predictive and prognostic immune module in HER2-positive BC confirms the need for clinical testing for immune checkpoint modulators and vaccines for this specific subtype. The inverse correlation between Immunity and hormone pathways opens research perspectives and deserves further investigation.
format Online
Article
Text
id pubmed-5178998
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-51789982017-01-04 A Stromal Immune Module Correlated with the Response to Neoadjuvant Chemotherapy, Prognosis and Lymphocyte Infiltration in HER2-Positive Breast Carcinoma Is Inversely Correlated with Hormonal Pathways Hamy, Anne-Sophie Bonsang-Kitzis, Hélène Lae, Marick Moarii, Matahi Sadacca, Benjamin Pinheiro, Alice Galliot, Marion Abecassis, Judith Laurent, Cecile Reyal, Fabien PLoS One Research Article INTRODUCTION: HER2-positive breast cancer (BC) is a heterogeneous group of aggressive breast cancers, the prognosis of which has greatly improved since the introduction of treatments targeting HER2. However, these tumors may display intrinsic or acquired resistance to treatment, and classifiers of HER2-positive tumors are required to improve the prediction of prognosis and to develop novel therapeutic interventions. METHODS: We analyzed 2893 primary human breast cancer samples from 21 publicly available datasets and developed a six-metagene signature on a training set of 448 HER2-positive BC. We then used external public datasets to assess the ability of these metagenes to predict the response to chemotherapy (Ignatiadis dataset), and prognosis (METABRIC dataset). RESULTS: We identified a six-metagene signature (138 genes) containing metagenes enriched in different gene ontologies. The gene clusters were named as follows: Immunity, Tumor suppressors/proliferation, Interferon, Signal transduction, Hormone/survival and Matrix clusters. In all datasets, the Immunity metagene was less strongly expressed in ER-positive than in ER-negative tumors, and was inversely correlated with the Hormonal/survival metagene. Within the signature, multivariate analyses showed that strong expression of the “Immunity” metagene was associated with higher pCR rates after NAC (OR = 3.71[1.28–11.91], p = 0.019) than weak expression, and with a better prognosis in HER2-positive/ER-negative breast cancers (HR = 0.58 [0.36–0.94], p = 0.026). Immunity metagene expression was associated with the presence of tumor-infiltrating lymphocytes (TILs). CONCLUSION: The identification of a predictive and prognostic immune module in HER2-positive BC confirms the need for clinical testing for immune checkpoint modulators and vaccines for this specific subtype. The inverse correlation between Immunity and hormone pathways opens research perspectives and deserves further investigation. Public Library of Science 2016-12-22 /pmc/articles/PMC5178998/ /pubmed/28005906 http://dx.doi.org/10.1371/journal.pone.0167397 Text en © 2016 Hamy et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Hamy, Anne-Sophie
Bonsang-Kitzis, Hélène
Lae, Marick
Moarii, Matahi
Sadacca, Benjamin
Pinheiro, Alice
Galliot, Marion
Abecassis, Judith
Laurent, Cecile
Reyal, Fabien
A Stromal Immune Module Correlated with the Response to Neoadjuvant Chemotherapy, Prognosis and Lymphocyte Infiltration in HER2-Positive Breast Carcinoma Is Inversely Correlated with Hormonal Pathways
title A Stromal Immune Module Correlated with the Response to Neoadjuvant Chemotherapy, Prognosis and Lymphocyte Infiltration in HER2-Positive Breast Carcinoma Is Inversely Correlated with Hormonal Pathways
title_full A Stromal Immune Module Correlated with the Response to Neoadjuvant Chemotherapy, Prognosis and Lymphocyte Infiltration in HER2-Positive Breast Carcinoma Is Inversely Correlated with Hormonal Pathways
title_fullStr A Stromal Immune Module Correlated with the Response to Neoadjuvant Chemotherapy, Prognosis and Lymphocyte Infiltration in HER2-Positive Breast Carcinoma Is Inversely Correlated with Hormonal Pathways
title_full_unstemmed A Stromal Immune Module Correlated with the Response to Neoadjuvant Chemotherapy, Prognosis and Lymphocyte Infiltration in HER2-Positive Breast Carcinoma Is Inversely Correlated with Hormonal Pathways
title_short A Stromal Immune Module Correlated with the Response to Neoadjuvant Chemotherapy, Prognosis and Lymphocyte Infiltration in HER2-Positive Breast Carcinoma Is Inversely Correlated with Hormonal Pathways
title_sort stromal immune module correlated with the response to neoadjuvant chemotherapy, prognosis and lymphocyte infiltration in her2-positive breast carcinoma is inversely correlated with hormonal pathways
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5178998/
https://www.ncbi.nlm.nih.gov/pubmed/28005906
http://dx.doi.org/10.1371/journal.pone.0167397
work_keys_str_mv AT hamyannesophie astromalimmunemodulecorrelatedwiththeresponsetoneoadjuvantchemotherapyprognosisandlymphocyteinfiltrationinher2positivebreastcarcinomaisinverselycorrelatedwithhormonalpathways
AT bonsangkitzishelene astromalimmunemodulecorrelatedwiththeresponsetoneoadjuvantchemotherapyprognosisandlymphocyteinfiltrationinher2positivebreastcarcinomaisinverselycorrelatedwithhormonalpathways
AT laemarick astromalimmunemodulecorrelatedwiththeresponsetoneoadjuvantchemotherapyprognosisandlymphocyteinfiltrationinher2positivebreastcarcinomaisinverselycorrelatedwithhormonalpathways
AT moariimatahi astromalimmunemodulecorrelatedwiththeresponsetoneoadjuvantchemotherapyprognosisandlymphocyteinfiltrationinher2positivebreastcarcinomaisinverselycorrelatedwithhormonalpathways
AT sadaccabenjamin astromalimmunemodulecorrelatedwiththeresponsetoneoadjuvantchemotherapyprognosisandlymphocyteinfiltrationinher2positivebreastcarcinomaisinverselycorrelatedwithhormonalpathways
AT pinheiroalice astromalimmunemodulecorrelatedwiththeresponsetoneoadjuvantchemotherapyprognosisandlymphocyteinfiltrationinher2positivebreastcarcinomaisinverselycorrelatedwithhormonalpathways
AT galliotmarion astromalimmunemodulecorrelatedwiththeresponsetoneoadjuvantchemotherapyprognosisandlymphocyteinfiltrationinher2positivebreastcarcinomaisinverselycorrelatedwithhormonalpathways
AT abecassisjudith astromalimmunemodulecorrelatedwiththeresponsetoneoadjuvantchemotherapyprognosisandlymphocyteinfiltrationinher2positivebreastcarcinomaisinverselycorrelatedwithhormonalpathways
AT laurentcecile astromalimmunemodulecorrelatedwiththeresponsetoneoadjuvantchemotherapyprognosisandlymphocyteinfiltrationinher2positivebreastcarcinomaisinverselycorrelatedwithhormonalpathways
AT reyalfabien astromalimmunemodulecorrelatedwiththeresponsetoneoadjuvantchemotherapyprognosisandlymphocyteinfiltrationinher2positivebreastcarcinomaisinverselycorrelatedwithhormonalpathways
AT hamyannesophie stromalimmunemodulecorrelatedwiththeresponsetoneoadjuvantchemotherapyprognosisandlymphocyteinfiltrationinher2positivebreastcarcinomaisinverselycorrelatedwithhormonalpathways
AT bonsangkitzishelene stromalimmunemodulecorrelatedwiththeresponsetoneoadjuvantchemotherapyprognosisandlymphocyteinfiltrationinher2positivebreastcarcinomaisinverselycorrelatedwithhormonalpathways
AT laemarick stromalimmunemodulecorrelatedwiththeresponsetoneoadjuvantchemotherapyprognosisandlymphocyteinfiltrationinher2positivebreastcarcinomaisinverselycorrelatedwithhormonalpathways
AT moariimatahi stromalimmunemodulecorrelatedwiththeresponsetoneoadjuvantchemotherapyprognosisandlymphocyteinfiltrationinher2positivebreastcarcinomaisinverselycorrelatedwithhormonalpathways
AT sadaccabenjamin stromalimmunemodulecorrelatedwiththeresponsetoneoadjuvantchemotherapyprognosisandlymphocyteinfiltrationinher2positivebreastcarcinomaisinverselycorrelatedwithhormonalpathways
AT pinheiroalice stromalimmunemodulecorrelatedwiththeresponsetoneoadjuvantchemotherapyprognosisandlymphocyteinfiltrationinher2positivebreastcarcinomaisinverselycorrelatedwithhormonalpathways
AT galliotmarion stromalimmunemodulecorrelatedwiththeresponsetoneoadjuvantchemotherapyprognosisandlymphocyteinfiltrationinher2positivebreastcarcinomaisinverselycorrelatedwithhormonalpathways
AT abecassisjudith stromalimmunemodulecorrelatedwiththeresponsetoneoadjuvantchemotherapyprognosisandlymphocyteinfiltrationinher2positivebreastcarcinomaisinverselycorrelatedwithhormonalpathways
AT laurentcecile stromalimmunemodulecorrelatedwiththeresponsetoneoadjuvantchemotherapyprognosisandlymphocyteinfiltrationinher2positivebreastcarcinomaisinverselycorrelatedwithhormonalpathways
AT reyalfabien stromalimmunemodulecorrelatedwiththeresponsetoneoadjuvantchemotherapyprognosisandlymphocyteinfiltrationinher2positivebreastcarcinomaisinverselycorrelatedwithhormonalpathways